Standard Glass Lining Share: Standard Glass Lining Technology Limited (SGLTL) has released the third quarter results for the first time after successful listing on NSE and BSE. The company’s consolidated net profit increased by 25.02 per cent to Rs 14.99 crore in the December 2024 quarter. Whereas in the last quarter ended December 2023 it was Rs 11.99 crore. At the same time, sales increased by 1.81% to Rs 140.14 crore, while it was Rs 137.65 crore during the last quarter ended December 2023.
The company’s shares declined by 2.49 per cent today amid heavy selling in the stock market and it closed at Rs 156.30. Its market cap is Rs 3,118.05 crore.
How to result in 9m FY25
The company’s total revenue has increased by 33 per cent to Rs 454.93 crore in a period of 9 months ended on 31 December. At the same time, in the same period, the company’s PAT increased by 45% per cent to Rs 52.15 crore on a annual basis. Ebitda of Standard Glass Lining Technology increased by 42 per cent to Rs 91.37 crore in a period of 9 months ended on 31 December. At the same time, its margin increased by 20.09 percent.
Preparation to install new subsidiary in USA
The company said that it has recently raised ₹ 210 crore through the IPO, which has promoted its development initiative. Along with this, the company is trying to establish a new subsidiary company in the USA to strengthen exports, which is planned to complete by the fourth quarter of FY 25.
SGLTL’s listing was made fantastic
Standard Glass Lining Technology makes engineering equipment for pharma and chemical sector companies. The company shares had a great listing in the stock market. Shares have been issued at a price of Rs 140 under the IPO. It has entered BSE at Rs 176.00 and NSE at Rs 172.00 i.e. IPO investors got more than 25 per cent listing gains. Its IPO received more than 185 times the overall.
About Standard Glass Lining
Standard Glass Lining in September 2012 makes engineering equipment for pharma and chemical sector. It provides services from design, engineering, manufacturing assembly, installation and standard operating projects. Its customers are veteran companies like Aurobindo Pharma, Lauras Labs, Natco Pharma, Piramal Pharma and Vavansh Life Sciences. It has 8 manufacturing units in Hyderabad, Telangana.
Disclaimer: Here information provided is being given only for information. It is necessary to mention here that the investment market in the market is subject to risks. Always consult experts before investing money as an investor. There is never advice to anyone to invest money on behalf of Moneycontrol.